Inhibikase Therapeutics, Inc. (IKT)

Inhibikase Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	0.26	0.12	3.1	0.7
Revenue Growth (YoY)	-	111.03%	-96.02%	343.92%	-37.79%
Cost of Revenue	17.21	13.62	12.03	11.36	0.89
Gross Profit	-17.21	-13.36	-11.91	-8.26	-0.2
Selling, General & Admin	11.38	6.73	6.22	6.51	2.62
Operating Expenses	11.38	6.73	6.22	6.51	2.62
Operating Income	-28.59	-20.09	-18.13	-14.77	-2.82
Interest Expense	-	-	-	-0.02	-0.03
Interest & Investment Income	1.07	1.06	0.07	-	-
Pretax Income	-27.52	-19.03	-18.05	-14.79	-2.85
Net Income	-27.52	-19.03	-18.05	-14.79	-2.85
Net Income to Common	-27.52	-19.03	-18.05	-14.79	-2.85
Shares Outstanding (Basic)	24	6	4	3	1
Shares Outstanding (Diluted)	24	6	4	3	1
Shares Change (YoY)	293.35%	42.74%	39.15%	121.72%	0.39%
EPS (Basic)	-1.16	-3.16	-4.28	-4.87	-2.08
EPS (Diluted)	-1.16	-3.16	-4.28	-4.87	-2.08
Free Cash Flow	-19.15	-18.1	-17.59	-14.3	-1.13
Free Cash Flow Per Share	-0.81	-3.00	-4.17	-4.71	-0.82
Gross Margin	-	-	-	-266.35%	-27.97%
Operating Margin	-	-7711.98%	-14686.17%	-476.23%	-403.52%
Profit Margin	-	-7304.73%	-14625.86%	-476.88%	-407.73%
Free Cash Flow Margin	-	-6947.87%	-14253.37%	-461.10%	-161.69%
EBITDA	-28.56	-19.91	-18.12	-	-
D&A For EBITDA	0.03	0.18	0.01	-	-
EBIT	-28.59	-20.09	-18.13	-14.77	-2.82
Revenue as Reported	-	0.26	0.12	3.1	0.7

Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q